MedTrace Logo

Pharmacokinetics of Certoparin in Subjects With Renal Insufficiency and Healthy Subjects

NCT01660295 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2012-08-08

No results posted yet for this study

Summary

This study will assess the pharmacokinetics in subjects with severe renal insufficiency and healthy subjects.

Conditions

  • Renal Insufficiency

Interventions

DRUG

Certoparin 3,000 IU Once Daily

Certoparin 3,000 IU subcutaneous injection once daily

DRUG

Certoparin 3,000 IU Twice a Day

Certoparin 3,000 IU subcutaneous injection twice a day

DRUG

Certoparin 8,000 IU Once Daily

Certoparin 8,000 IU subcutaneous injection once daily

DRUG

Certoparin 8,000 IU Twice a Day

Certoparin 8,000 IU subcutaneous injection twice a day

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2012-06-30

Countries

  • Hungary

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01660295 on ClinicalTrials.gov